*Feature is not available in all countries
Contact our local representative for more study results.
1. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.Nephrol Dial Transplant2000;15:1207-1211.
2. Ģý. Unpublished internal data on file.
3. Ledebo I. and Ward R.A., Dialysis Ģý History, Development and Promise,World Scientific Publishing(2012); Chapter 5N: 481-489.
4. Jofré R, Rodriguez-Benitez P, López-Gómez J, Pérez García R.. Inflammatory syndrome in patients on hemodialysis.J Am Soc Nephrol2006;17:274-280.
5. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation.Nephron2002;91:452-455.
6. Furuya R et al. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients.Blood Purif2005;23:311-316.
7. Scarpioni R et al. Dialysis-related amyloidosis: challenges and solutions.Int J Nephrol Renovasc Dis2016;9:319-328.
8. Shafi T et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.Am J Kidney Dis2010;56:348-358.
9. Liu X, Dai C. Advances in understanding and management of residual renalfunction in patients with chronic kidney disease.Kidney Dis2017;2:187-196.
10. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients.Nephrol Dial Transplant2002;17:1814-1818.
11 Canaud et al. Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy.Nephrol. Dial. Transplant.: 16, 2181-2187, 2001.